BioCryst Pharmaceuticals

Yahoo Finance • yesterday

BioCryst (BCRX) Soars 10.8% on Swing to Profits

We recently published 10 Stocks Ending February With a Bang. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) was one of the best performers on Friday. BioCryst surged by 10.76 percent on Friday to close at $8.75 apiece, as investor sentiment... Full story

Yahoo Finance • 3 days ago

BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances

Earnings Call Insights: BioCryst Pharmaceuticals (BCRX) Q4 2025 MANAGEMENT VIEW * Charles Gayer, CEO, emphasized, "We closed 2025 with strong momentum, delivering full-year ORLADEYO revenue of $601.8 million. That was up 38% for the ye... Full story

Yahoo Finance • 4 days ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VI... Full story

Yahoo Finance • 4 days ago

BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed?

Evercore ISI recently reinstated coverage of BioCryst Pharmaceuticals, highlighting the company’s position after its acquisition of Astria Therapeutics and its hereditary angioedema portfolio, including ORLADEYO and navenibart. BioCryst is... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best small cap stocks to buy with huge upside potential. H.C. Wainwright lifted the price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $32 from $30 on December 15, and r... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: Spotlight on the Fed, Costco earnings, and Nasdaq 100 additions

[Amazing golden hour in modern New York. Sunset time footage from drone. Setting sun dazzles the scenery.] Vadym Terelyuk/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable ev... Full story

Yahoo Finance • 3 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees stock optio... Full story

Yahoo Finance • 3 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements... Full story

Yahoo Finance • 3 months ago

Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 4 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * ON Semiconductor Corporation (ON [https://seekingalpha.com/symbol/ON]) * Oxford Lane Capital Corp. (OXLC [https://seekingalpha.com/symbol/OXLC]) * fuboTV (FUBO [https://se... Full story

Yahoo Finance • 4 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

BALA CYNWYD, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 4 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

BALA CYNWYD, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 4 months ago

Key deals this week: Paramount Skydance, PotlatchDeltic, Brighthouse Financial, Papa John's and more

Here's a list of key deals reported across sectors this week: * Paramount Skydance (NASDAQ:PSKY [https://seekingalpha.com/symbol/PSKY]) is preparing a second bid [https://seekingalpha.com/news/4503595-paramount-skydance-preparing-second... Full story

Yahoo Finance • 4 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)

BALA CYNWYD, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 5 months ago

BioCryst to buy Astria Therapeutics for $13 per share (update)

_UPDATE: ADDS SHARE MOVEMENTS_ BioCryst Pharmaceuticals (NASDAQ:BCRX [https://seekingalpha.com/symbol/BCRX]) has agreed to acquire biopharmaceutical firm Astria Therapeutics (NASDAQ:ATXS [https://seekingalpha.com/symbol/ATXS]) for a mix o... Full story

Yahoo Finance • 5 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – Bio... Full story

Yahoo Finance • 5 months ago

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best stocks to buy under $20. On October 1, BioCryst Pharmaceuticals announced the successful completion of the previously announced sale of its European ORLADEYO (berotralstat) bus... Full story

Yahoo Finance • 5 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

– Transaction valued at $250 million, with up to $14 million in future milestones – – BioCryst will focus on driving ORLADEYO sales in the U.S. while Neopharmed Gentili will lead commercialization across Europe – – Provides a significant... Full story

Yahoo Finance • 6 months ago

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September... Full story

Yahoo Finance • 7 months ago

BioCryst Announces Departure of Dr. Helen Thackray

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and t... Full story